Search results
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock...
Digital Journal· 2 weeks ago(NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and